Methods of using factor b inhibitors

EP4766364A1Pending Publication Date: 2026-07-01NOVARTIS AG
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
EP · EP
Patent Type
Applications
Current Assignee / Owner
NOVARTIS AG
Filing Date
2024-08-23
Publication Date
2026-07-01

AI Technical Summary

Technical Problem

Current treatments for Myasthenia Gravis (MG), particularly generalized Myasthenia Gravis (gMG), are limited by their non-specific immune suppression, associated side effects, and the need for frequent administration of intravenous or subcutaneous injections, which can be burdensome for patients.

Method used

The use of iptacopan, a Factor B inhibitor, administered orally, to treat gMG by reducing the Myasthenia Gravis Activity of Daily Living (MG-ADL) total score and Quantitative Myasthenia Gravis (QMG) total score, thereby improving patient outcomes without the adverse effects of traditional therapies.

Benefits of technology

Iptacopan effectively reduces the MG-ADL and QMG total scores, indicating improved muscle strength and reduced daily living impairments in gMG patients, with a potentially more favorable safety profile compared to existing treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000028_0001
    Figure IMGF000028_0001
  • Figure IMGF000029_0001
    Figure IMGF000029_0001
  • Figure 00000092_0000
    Figure 00000092_0000
Patent Text Reader

Abstract

Described herein are methods of treating gMG (generalized Myasthenia gravis) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt or hydrate thereof.
Need to check novelty before this filing date? Find Prior Art